SCHEMBL2176166

SCHEMBL2176166

CCN1C(=O)SC(=Cc2ccc(O)c(Br)c2)C1=O

nearest known ligand 0.61

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 6/20 0.61
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
ATM Q13315 1/20 0.58
BAG3 O95817 1/20 0.58
CGAS Q8N884 1/20 0.58
ALDH1A1 P00352 1/20 0.55
PDE4B Q07343 2/20 0.55
COMT P21964 1/20 0.55
SLC2A1 P11166 1/20 0.54
CISD1 Q9NZ45 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2176164 1.00 HSD17B3 (0.61) HSD17B3MEN1KMT2AATMBAG3
SCHEMBL2174023 0.91 HSD17B3 (0.62) HSD17B3MEN1KMT2AATMBAG3
SCHEMBL2174019 0.91 HSD17B3 (0.62) HSD17B3MEN1KMT2AATMBAG3
SCHEMBL2174117 0.88 HSD17B3 (0.59) HSD17B3MEN1KMT2AATMBAG3
SCHEMBL2174120 0.88 HSD17B3 (0.59) HSD17B3MEN1KMT2AATMBAG3
SCHEMBL2176135 0.87 HSD17B3 (0.58) HSD17B3MEN1KMT2AATMBAG3
SCHEMBL2176138 0.87 HSD17B3 (0.58) HSD17B3MEN1KMT2AATMBAG3
SCHEMBL2175305 0.85 HSD17B3 (0.59) HSD17B3MEN1KMT2AATMBAG3
SCHEMBL2175308 0.85 HSD17B3 (0.59) HSD17B3MEN1KMT2AATMBAG3
SCHEMBL2171857 0.85 HSD17B3 (0.79) HSD17B3MEN1KMT2AATMBAG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2254576-B1 ANDROGEN RECEPTOR-ABLATIVE AGENTS UNIV OHIO STATE RES FOUND (US) 2013-08-28 EP claimed
US-7973062-B2 Androgen receptor-ablative agents THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-07-05 US claimed
EP-2254576-A1 ANDROGEN RECEPTOT-ABLATIVE AGENTS The Ohio State University Research Foundation (US) 2010-12-01 EP claimed
US-20090291992-A1 ANDROGEN RECEPTOR-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-11-26 US claimed
WO-2009105621-A1 ANDROGEN RECEPTOT-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-08-27 WO claimed
EP-2254576-B1 ANDROGEN RECEPTOR-ABLATIVE AGENTS UNIV OHIO STATE RES FOUND (US) 2013-08-28 EP disclosed
US-7973062-B2 Androgen receptor-ablative agents THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-07-05 US disclosed
EP-2254576-A1 ANDROGEN RECEPTOT-ABLATIVE AGENTS The Ohio State University Research Foundation (US) 2010-12-01 EP disclosed
US-20090291992-A1 ANDROGEN RECEPTOR-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-11-26 US disclosed
WO-2009105621-A1 ANDROGEN RECEPTOT-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291992-A1 ANDROGEN RECEPTOR-ABLATIVE AGENTS AR, ESRRB, KLK3 HSD17B3 48/4885MEN1 2122/4885KMT2A 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.